Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Midazolam + Ziftomenib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Midazolam | Dormicum | Dea No. 2884 | ||
| Ziftomenib | Komzifti | KO539|KO 539|KO-539 | MEN1-KMT2A Inhibitor 8 | Komzifti (ziftomenib) is a small molecule inhibitor of MEN1 (menin)-KMT2A (MLL1) complex, which may lead to decreased growth KMT2A (MLL1)-positive tumor cells, and inhibition of tumor growth (PMID: 36151141). Komzifti (ziftomenib) is FDA-approved for use in patients with relapsed/refractory acute myeloid leukemia harboring a susceptible NPM1 mutation (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04067336 | Phase Ib/II | Itraconazole + Ziftomenib Ziftomenib Midazolam + Ziftomenib | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |